Cargando…

The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence

SIMPLE SUMMARY: PSMA-PET is currently recommended to restage PCa and to guide salvage treatments. We aim to evaluate the oncologic outcomes of patients with recurrent PCa who received PSMA-PET. PSMA-PET may be a prognostic tool in BCR patients after PR. In recurrent PCa patients who never received p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bianchi, Lorenzo, Ceci, Francesco, Costa, Francesco, Balestrazzi, Eleonora, Droghetti, Matteo, Piazza, Pietro, Pissavini, Alessandro, Mei, Riccardo, Farolfi, Andrea, Castellucci, Paolo, Puliatti, Stefano, Larcher, Alessandro, Gandaglia, Giorgio, Robesti, Daniele, Mottrie, Alexandre, Briganti, Alberto, Morganti, Alessio Giuseppe, Fanti, Stefano, Montorsi, Francesco, Schiavina, Riccardo, Brunocilla, Eugenio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818949/ https://www.ncbi.nlm.nih.gov/pubmed/36612242 http://dx.doi.org/10.3390/cancers15010247

Ejemplares similares

PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment
por: Bianchi, Lorenzo, et al.
Publicado: (2023)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
por: Vetrone, Luigia, et al.
Publicado: (2023)

Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
por: Gandaglia, Giorgio, et al.
Publicado: (2023)

Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course
por: Gandaglia, Giorgio, et al.
Publicado: (2022)

Prostate Cancer: Is There Still a Role for Systematic Biopsies? Yes
por: Gandaglia, Giorgio, et al.
Publicado: (2022)

A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer Patients
por: Serani, Francesca, et al.
Publicado: (2023)

3D renal model for surgical planning of partial nephrectomy: A way to improve surgical outcomes
por: Bianchi, Lorenzo, et al.
Publicado: (2022)

Twenty Years’ Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center
por: Mottaran, Angelo, et al.
Publicado: (2023)

Anastomotic leaks and catheter time after salvage robot-assisted radical prostatectomy
por: Bandini, Marco, et al.
Publicado: (2018)

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer
por: Bandini, Marco, et al.
Publicado: (2017)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Radioguided surgery with β radiation: a novel application with Ga(68)
por: Collamati, Francesco, et al.
Publicado: (2018)

The Effect of Anatomical Location of Lymph Node Metastases on Cancer Specific Survival in Patients with Clear Cell Renal Cell Carcinoma
por: Nini, Alessandro, et al.
Publicado: (2018)

A case report of myoid gonadal stromal tumor treated with testis sparing surgery
por: Ercolino, Amelio, et al.
Publicado: (2022)

Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer
por: Bravi, Carlo A., et al.
Publicado: (2022)

(18)F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study
por: Zattoni, Fabio, et al.
Publicado: (2019)

The Learning Curve for Radical Nephrectomy for Kidney Cancer: Implications for Surgical Training
por: Larcher, Alessandro, et al.
Publicado: (2023)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

What to Trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from Experience
por: Viglialoro, Rita, et al.
Publicado: (2021)

Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer
por: Scuderi, Simone, et al.
Publicado: (2023)

Multiparametric magnetic resonance imaging for the differential diagnosis between granulomatous prostatitis and prostate cancer: a literature review to an intriguing diagnostic challenge
por: Gaudiano, Caterina, et al.
Publicado: (2023)

Cytoreductive Nephrectomy in 2021: Obsolete but Necessary
por: Capitanio, Umberto, et al.
Publicado: (2021)

TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?—a narrative review
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice
por: Gómez Rivas, Juan, et al.
Publicado: (2022)

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
por: Mollica, Veronica, et al.
Publicado: (2020)

A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study
por: Bicchetti, Marco, et al.
Publicado: (2022)

Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge
por: Vetrone, Luigia, et al.
Publicado: (2023)

Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging
por: Gaudiano, Caterina, et al.
Publicado: (2023)

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
por: Ceci, Francesco, et al.
Publicado: (2021)

The IRON Study: Investigation of Robot-assisted Versus Open Nephron-sparing Surgery
por: Bravi, Carlo Andrea, et al.
Publicado: (2023)

Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
por: Lilleby, Oscar, et al.
Publicado: (2019)

Selecting the Most Appropriate Oncological Treatment for Patients with Renal Masses During the COVID-19 Pandemic: Recommendations from a Referral Center
por: Moschovas, Marcio Covas, et al.
Publicado: (2020)

Penile rehabilitation after radical prostatectomy: does it work?
por: Gandaglia, Giorgio, et al.
Publicado: (2015)

Antihormone treatment differentially regulates PSA secretion, PSMA expression and (68)Ga–PSMA uptake in LNCaP cells
por: Mathy, C. S., et al.
Publicado: (2021)

Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative?—a narrative review
por: Pellegrino, Antony, et al.
Publicado: (2022)

PSA mass screening: is there enough evidence?
por: Rocco, Bernardo, et al.
Publicado: (2012)

A Comparison of the Biological Features of Prostate Cancer with (PSA+, PSMA+) Profile according to RKIP
por: Ben Jemaa, Awatef, et al.
Publicado: (2013)

Diagnostic Efficacy of PSMA and PSCA mRNAs Combined to PSA in Prostate Cancer Patients
por: Mahmoud, Mustafa M, et al.
Publicado: (2023)

Unexpected Outcomes of Renal Function after Radical Nephrectomy: Histology Relevance along with Clinical Aspects
por: Di Marco, Federico, et al.
Publicado: (2021)

PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
por: Hoffmann, Manuela Andrea, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m0hlca4htbu6v3ad46nldffjrk